Literature DB >> 10820016

Role of the kidney in regulating the metabolism of HDL in rabbits: evidence that iodination alters the catabolism of apolipoprotein A-I by the kidney.

S Braschi1, T A Neville, C Maugeais, T A Ramsamy, R Seymour, D L Sparks.   

Abstract

To evaluate the factors that regulate HDL catabolism in vivo, we have measured the clearance of human apoA-I from rabbit plasma by following the isotopic decay of (125)I-apoA-I and the clearance of unlabeled apoA-I using a radioimmunometric assay (RIA). We show that the clearance of unlabeled apoA-I is 3-fold slower than that of (125)I-apoA-I. The mass clearance of iodinated apoA-I, as determined by RIA, is superimposable with the isotopic clearance of (125)I-apoA-I. The data demonstrate that iodination of tyrosine residues alters the apoA-I molecule in a manner that promotes an accelerated catabolism. The clearance from rabbit plasma of unmodified apoA-I on HDL(3) and a reconstituted HDL particle (LpA-I) were very similar and about 3-4-fold slower than that for (125)I-apoA-I on the lipoproteins. Therefore, HDL turnover in the rabbit is much slower than that estimated from tracer kinetic studies. To determine the role of the kidney in HDL metabolism, the kinetics of unmodified apoA-I and LpA-I were reevaluated in animals after a unilateral nephrectomy. Removal of one kidney was associated with a 40-50% reduction in creatinine clearance rates and a 34% decrease in the clearance rate of unlabeled apoA-I and LpA-I particles. In contrast, the clearance of (125)I-labeled molecules was much less affected by the removal of a kidney; FCR for (125)I-LpA-I was reduced by <10%. The data show that the kidneys are responsible for most (70%) of the catabolism of apoA-I and HDL in vivo, while (125)I-labeled apoA-I and HDL are rapidly catabolized by different tissues. Thus, the kidney is the major site for HDL catabolism in vivo. Modification of tyrosine residues on apoA-I may increase its plasma clearance rate by enhancing extra-renal degradation pathways.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10820016     DOI: 10.1021/bi9919504

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  12 in total

1.  Lower HDL-C and apolipoprotein A-I are related to higher glomerular filtration rate in subjects without kidney disease.

Authors:  Jan A Krikken; Ron T Gansevoort; Robin P F Dullaart
Journal:  J Lipid Res       Date:  2010-03-08       Impact factor: 5.922

Review 2.  Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein.

Authors:  Valentina Kon; Haichun Yang; Sergio Fazio
Journal:  Arch Med Res       Date:  2015-05-23       Impact factor: 2.235

3.  In Vivo PET Imaging of HDL in Multiple Atherosclerosis Models.

Authors:  Carlos Pérez-Medina; Tina Binderup; Mark E Lobatto; Jun Tang; Claudia Calcagno; Luuk Giesen; Chang Ho Wessel; Julia Witjes; Seigo Ishino; Samantha Baxter; Yiming Zhao; Sarayu Ramachandran; Mootaz Eldib; Brenda L Sánchez-Gaytán; Philip M Robson; Jason Bini; Juan F Granada; Kenneth M Fish; Erik S G Stroes; Raphaël Duivenvoorden; Sotirios Tsimikas; Jason S Lewis; Thomas Reiner; Valentín Fuster; Andreas Kjær; Edward A Fisher; Zahi A Fayad; Willem J M Mulder
Journal:  JACC Cardiovasc Imaging       Date:  2016-05-25

4.  PET Imaging of Tumor-Associated Macrophages with 89Zr-Labeled High-Density Lipoprotein Nanoparticles.

Authors:  Carlos Pérez-Medina; Jun Tang; Dalya Abdel-Atti; Brandon Hogstad; Miriam Merad; Edward A Fisher; Zahi A Fayad; Jason S Lewis; Willem J M Mulder; Thomas Reiner
Journal:  J Nucl Med       Date:  2015-06-25       Impact factor: 10.057

5.  A pivotal role of the human kidney in catabolism of HDL protein components apolipoprotein A-I and A-IV but not of A-II.

Authors:  Jonas Heilskov Graversen; Graciela Castro; Abdelmejid Kandoussi; Henning Nielsen; Erik Ilsø Christensen; Anthony Norden; Søren Kragh Moestrup
Journal:  Lipids       Date:  2008-03-19       Impact factor: 1.880

6.  An analysis of the role of a retroendocytosis pathway in ABCA1-mediated cholesterol efflux from macrophages.

Authors:  Loren E Faulkner; Stacey E Panagotopulos; Jacob D Johnson; Laura A Woollett; David Y Hui; Scott R Witting; J Nicholas Maiorano; W Sean Davidson
Journal:  J Lipid Res       Date:  2008-03-22       Impact factor: 5.922

7.  Evaluation of apolipoprotein A-I kinetics in rabbits in vivo using in situ and exogenous radioiodination methods.

Authors:  Bo Zhang; Eiso Shimoji; Hiroaki Tanaka; Keijiro Saku
Journal:  Lipids       Date:  2003-03       Impact factor: 1.880

8.  The lipid composition of high-density lipoprotein affects its re-absorption in the kidney by proximal tubule epithelial cells.

Authors:  Dalibor Breznan; Vasanthi Veereswaran; France J Viau; Tracey A-M Neville; Daniel L Sparks
Journal:  Biochem J       Date:  2004-04-15       Impact factor: 3.857

Review 9.  Managing diabetic dyslipidemia: beyond statin therapy.

Authors:  Hemanth Neeli; Ram Gadi; Daniel J Rader
Journal:  Curr Diab Rep       Date:  2009-02       Impact factor: 4.810

10.  An in-silico model of lipoprotein metabolism and kinetics for the evaluation of targets and biomarkers in the reverse cholesterol transport pathway.

Authors:  James Lu; Katrin Hübner; M Nazeem Nanjee; Eliot A Brinton; Norman A Mazer
Journal:  PLoS Comput Biol       Date:  2014-03-13       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.